Trial Profile

A phase 3 head to head study of Anruixi study with Rituximab for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zuberitamab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors BioRay Pharmaceutical

Most Recent Events

18 Sep 2023 New trial record
13 Sep 2023 Results presented in a BioRay Pharmaceutical media release.
13 Sep 2023 According to a BioRay Pharmaceutical media release, the study was conducted in 43 study sites nationwide.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com